Lucinda Camidge
Adelphi Group (United Kingdom)(GB)
Publications by Year
Research Areas
Chronic Obstructive Pulmonary Disease (COPD) Research, Asthma and respiratory diseases, Inhalation and Respiratory Drug Delivery, Pneumonia and Respiratory Infections, Acute Myeloid Leukemia Research
Most-Cited Works
- → Curation and analysis of clinical pathology parameters and histopathologic findings from eTOXsys, a large database project (eTOX) for toxicologic studies(2019)13 cited
- → Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study(2023)12 cited
- → Benefit of Prompt Vs Delayed Initiation of Triple Therapy Following an Exacerbation in Patients with COPD in Japan: A Retrospective Cohort Study(2023)11 cited
- → Comparative adherence and persistence of single-inhaler and multiple-inhaler triple therapies among patients with chronic obstructive pulmonary disease in Japan: a retrospective cohort study(2024)7 cited
- → Outcomes of patients with COPD switching from multiple-inhaler to once-daily single-inhaler triple therapy in a real-world primary care setting in England: a retrospective pre-post cohort study(2024)5 cited
- → Effectiveness of Switching from Multiple-Inhaler to Once-Daily Single-Inhaler Triple Therapy in Patients with COPD in a Real-World Setting in Japan(2025)3 cited
- → Treatment Inertia and Symptom Burden in Anemia of CKD: Insights from the SATISFY Survey in the Middle East, South Africa, and Türkiye(2025)1 cited
- → #3156 REAL WORLD CHARACTERISTICS, SYMPTOM BURDEN AND TREATMENT PATTERNS OF ANAEMIA OF CKD IN EGYPT, SAUDI ARABIA, SOUTH AFRICA, AND TURKEY(2023)1 cited
- → Reduced exacerbations following switch from multiple-inhaler to once-daily single-inhaler triple therapy in COPD patients in a real-world primary care setting in England(2022)1 cited
- → Adherence to single and multiple inhaler triple therapies among patients with COPD in the real world in Japan(2023)1 cited